Exelon® Granted EU Marketing Authorization As First Treatment For Dementia Associated With Parkinson''s Disease By European Commission

... Novartis announced today that Exelon®(rivastigmine tartrate) has been granted European marketing authorizationby the European Commission for the symptomatic treatment of mild tomoderately severe dementia in patients with idiopathic Parkinson''s disease(PD) in all 25 European member states. This makes Exelon, currently indicated for Alzheimer''s dementia, the firstmedication available to treat dementia in Parkinson''s patients in theEuropean Union and the only cholinesterase inhibitor to be authorized formore than one type of dementia... click link for more info. ...